Legend Biotech Corp
NASDAQ:LEGN
Legend Biotech Corp
NASDAQ:LEGN
Price:
42.6 USD
-0.14%
Market Closed
Updated:
May 23, 2024
Legend Biotech Corp
Total Current Liabilities
|
Legend Biotech Corp
Total Current Liabilities Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Total Current Liabilities Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Legend Biotech Corp
NASDAQ:LEGN
|
Total Current Liabilities
$216.4m
|
CAGR 3-Years
23%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Total Current Liabilities
$41.5B
|
CAGR 3-Years
9%
|
CAGR 5-Years
24%
|
CAGR 10-Years
21%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Total Current Liabilities
$13B
|
CAGR 3-Years
10%
|
CAGR 5-Years
7%
|
CAGR 10-Years
8%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Total Current Liabilities
$19.7B
|
CAGR 3-Years
15%
|
CAGR 5-Years
9%
|
CAGR 10-Years
9%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Total Current Liabilities
$3.8B
|
CAGR 3-Years
25%
|
CAGR 5-Years
28%
|
CAGR 10-Years
26%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Total Current Liabilities
$3.6B
|
CAGR 3-Years
4%
|
CAGR 5-Years
19%
|
CAGR 10-Years
28%
|
See Also
What is Legend Biotech Corp's Total Current Liabilities?
Total Current Liabilities
216.4m
USD
216.4m
USD
Based on the financial report for Dec 31, 2023, Legend Biotech Corp's Total Current Liabilities amounts to 216.4m USD.
What is Legend Biotech Corp's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 5Y
6%
6%
Over the last year, the Total Current Liabilities growth was -27%. The average annual Total Current Liabilities growth rates for Legend Biotech Corp have been 23% over the past three years , 6% over the past five years .
You don't have any saved screeners yet
